青光眼视神经保护离我们有多远

Glaucoma neuroprotection how far is it from a dream to reality

尽管在基础研究中，Memantine、Calpain、促红细胞生成素等药物均显现出喜人的青光眼视神经保护潜能，但随着Memantine等Ⅲ期临床试验的失败，目前仍无一种视神经保护药物能够通过美国食品药品管理局的审核批准并投入临床应用，使临床青光眼视神经保护的研究面临近乎尴尬的困境。青光眼视神经保护的迫切性要求我们必须从新的视角审视问题，充分利用人类基因组计划、蛋白质组计划、干细胞和转基因动物研究成果，对其实施分期靶点干预，以使青光眼视神经保护的梦想变成现实。

Although the durgs, such as Memantine, Calpain, Erythropoietin, have demonstrated exciting results for neuroprotection in laboratories, the phase Ⅲ clinical trial of Memantine failed to prove such activity. So far, none of neuroprotection drugs has been approved by FDA for clinical use with the failure of Memantine clinical trail indicating that the gap between basic science research and clinical application in glaucomatous optic neuroprotection remains to be filled. This paper offers a new insight into the field of neuroprotecion in glaucoma. To make the dream of optic neuroprotection to reality, we have to implement new perspective strategies to integrate technologies and findings from the researches of human genomonics, proteomics, stem cells, and gene-transferred animal models.